Cartalax vs Pentosan (Joint Pain)
A side-by-side research comparison of Cartalax and Pentosan (Joint Pain) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Cartalax | Pentosan (Joint Pain) |
|---|---|---|
| Full name | Cartalax (Ala-Glu-Asp-Gly Cartilage Bioregulator) | Pentosan Polysulfate Sodium (Cartrophen) |
| Category | Pain & Inflammation | Pain & Inflammation |
| Status | Research compound (peptide bioregulator) | FDA Approved (interstitial cystitis) / Veterinary approved |
| Mechanism | As a signal peptide (Ala-Glu-Asp-Gly), it is proposed to regulate gene expression in chondrocytes and connective tissue, supporting cartilage matrix maintenance and anti-inflammatory tissue signaling. | Inhibits matrix metalloproteinases (MMPs) and aggrecanases that degrade cartilage. Stimulates hyaluronic acid production by synoviocytes. Promotes proteoglycan synthesis by chondrocytes. Reduces subchondral bone remodeling via anti-inflammatory effects. |
| Molecular weight | ~390 Da | ~4000-6000 Da (average) |
| Half-life | Short (peptide) | ~24 hours |
| Bioavailability | Oral (encapsulated) or subcutaneous | ~6% oral; ~100% subcutaneous |
| Typical dose | ~1-2 capsules/day or short injectable courses | 2-3 mg/kg SC (veterinary extrapolation) or 100mg oral 3x/day |
| Frequency | Once daily | Weekly SC injections (4-6 course) or daily oral |
| Route | Oral capsule or subcutaneous | Subcutaneous injection or oral capsule |
Cartalax reported benefits
- Cartilage/joint tissue support
- Connective tissue maintenance (proposed)
- Anti-inflammatory tissue signaling
- Short course-based protocol
Pentosan (Joint Pain) reported benefits
- Cartilage protection and repair
- Reduced joint inflammation
- Improved synovial fluid
- Disease-modifying (not just symptomatic)
- Reduced bone marrow edema
- Alternative to corticosteroid injections
Related comparisons
Research and educational reference only. Not medical advice.